[Therapy of cystitis with nitroxoline-NitroxWin : Prospective, multicenter, non-interventional study and...

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Nitroxoline is a recommended first-choice antibiotic for uncomplicated cystitis (UC) in women per German guidelines.
• A noninterventional study (NIS) was conducted to evaluate nitroxoline's real-world clinical efficacy and monitor E. coli resistance.

Purpose of the Study:

• To assess the clinical effectiveness of nitroxoline in treating uncomplicated cystitis (UC) in women under real-world conditions.
• To monitor the prevalence of nitroxoline resistance in urinary E. coli isolates.

Main Methods:

• A prospective, multicenter, noninterventional study (NIS) included female patients with UC treated with nitroxoline (250 mg tid for 5 days).
• Clinical efficacy was assessed using the Acute Cystitis Symptom Score (ACSS) and laboratory tests over 21-28 days.
• A nationwide resistance surveillance collected and tested urinary E. coli isolates for nitroxoline susceptibility from 2019-2020.

Main Results:

• The NIS included 316 patients; clinical success rates were 86.3% (per-protocol) and 81.44% (intention-to-treat).
• Patient-reported tolerability of nitroxoline was rated "very good" or "good" by 96% of participants.
• All 272 tested E. coli isolates exhibited susceptibility to nitroxoline.

Conclusions:

• Nitroxoline achieved excellent clinical outcomes in the real-world NIS.
• 100% susceptibility of E. coli urine isolates to nitroxoline was confirmed.
• Nitroxoline remains a recommended first-line antibiotic for uncomplicated cystitis in women.